ArticleJournal of managed care & specialty pharmacy2026
AMCP Market Insights: The role of managed care in improving patient care in mucopolysaccharidoses.
Article in Journal of managed care & specialty pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- AMCP Market Insights: The role of managed care in improving patient care in mucopolysaccharidoses.Journal of managed care & specialty pharmacy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The mucopolysaccharidoses (MPS) are a group of rare genetic disorders that cause chronic, progressive cellular damage, which can affect multiple organ systems and lead to reduced life expectancy. Diagnosis and treatment of MPS are often delayed, during which irreversible organ damage can occur. Treatments are not currently available for all MPS subtypes, and those that are available are associated with significant limitations. The therapeutic pipeline for MPS is active; however, bringing new treatments for rare conditions to market is difficult. To discuss the role of managed care in improving patient care and outcomes in MPS, AMCP Market Insights virtually convened an expert panel of managed care stakeholders in September 2025. Key insights from the discussion were that the earliest possible intervention is crucial to improving outcomes in MPS; expertise is limited because of the rarity of these disorders; patients and caregivers face significant challenges accessing treatments and other interventions for MPS; and the therapeutic pipeline for MPS holds promise for addressing some critical treatment gaps but leaves others unmet. Suggested payer practices for MPS also emerged from the discussion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.